Lunit Inc. (KOSDAQ:A328130) agreed to acquire Volpara Health Technologies Limited (ASX:VHT) from Harbour Asset Management Limited and others for AUD 300 million on December 13, 2023. Volpara shareholder approval will be sought at a Scheme meeting of shareholders expected to be held in early Q2 2024. The proposed Scheme is subject to Volpara shareholder and Court approval, approval of the New Zealand Overseas Investment Office, a ?material adverse change?

condition, and other conditions as detailed in the Scheme Implementation Agreement. The Board is unanimous in its view that this transaction is in the best interests of Volpara shareholders. The Board unanimously recommends that shareholders vote in favour of the proposed Scheme, subject to the Scheme price being within or above the Independent Adviser?s valuation range for Volpara?s shares and in the absence of a superior proposal.

The Acquirer will at Implementation have available to it on an unconditional basis sufficient cash resources (whether from internal cash reserves or external funding arrangements or a combination of both) to satisfy the Acquirer s obligations to pay the Consideration in accordance with its obligations under this agreement, the Scheme and the Deed Poll. If all the conditions are satisfied, the proposed Scheme is expected to be implemented in Q2 2024. As of April 25, 2024, the transaction is expected to close on May 21, 2024.

Evercore GmbH acted as financial advisor to Volpara Health Technologies Limited.